CN112680529A - Quality control method of C3A cells required by biotype artificial liver treatment and application thereof - Google Patents
Quality control method of C3A cells required by biotype artificial liver treatment and application thereof Download PDFInfo
- Publication number
- CN112680529A CN112680529A CN202011619362.0A CN202011619362A CN112680529A CN 112680529 A CN112680529 A CN 112680529A CN 202011619362 A CN202011619362 A CN 202011619362A CN 112680529 A CN112680529 A CN 112680529A
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- virus
- detecting
- cell bank
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a quality control method of C3A cells required by biotype artificial liver treatment and application thereof. The C3A cells obtained by screening by the quality control method have good quality and high safety, and can be used for large-scale production and treatment of the biological artificial liver.
Description
Technical Field
The invention belongs to the field of biomedicine, and relates to a quality control method of C3A cells required by biotype artificial liver treatment and application thereof.
Background
The liver is a complex organ, composed of several different cell types, but the key is the hepatocyte, which plays most of its biochemical functions in the course of acute phase reactions, the production of coagulation factors and the biochemical reactions that take place for detoxification. When hepatocytes are cultured or expanded in vitro, their viability is limited because they quickly stop differentiating or die. Thus, liver assist products present practical and theoretical hurdles in using normal hepatocytes. Cell lines derived from well-differentiated liver tumor cells alleviate many of the practical and theoretical hurdles. The specific cell line selected for the human heterologous elad (extracorporeal Liver Assist device), human C3A cell line, was a subclone line of the human hepatoblastoma cell line HepG 2. C3A cells rapidly immortalize and retain the same liver function to facilitate the mass of cells grown in culture needed for subjects treated as a liver support system to perform impaired liver function and maintain cell proliferation, differentiation and metabolic activity during treatment.
Mutation, senescence and evolution occur continuously in all actively growing cell cultures. The longer the maintenance and amplification time, the more these changes accumulate. Thus, cell cultures often lose important genotypic and/or phenotypic characteristics, such as alterations in biochemical and functional properties. Cell lines derived from tumors or genetic engineering are particularly susceptible to genetic alterations. In addition to the effect on cell line characteristics, the use of an over-passaged cell line increases cell stability, the risk of cross-contamination of microorganisms, viruses or cells. A key step in controlling these problems and achieving "sourcing" or standardization of cell lines is the establishment and careful maintenance of frozen cell stocks for all key cell lines. A complete cell bank is essential to ensure that there is an adequate equivalent supply of cells throughout the life cycle of product production, and to maintain product quality and industrialization. The purpose of cell bank characterization is to determine the characteristics, purity and suitability of the cell matrix for production and use. Careful testing is required for thawed cells to verify the following: 1) activity; 2) no mycoplasma or other microbial contamination; 3) cell line identity; 4) important cell line characteristics to ensure stability of cell properties and safety of cell use.
Quality control of C3A cells required for ELAD is very important because only a sufficient stock of high quality C3A cells can meet the needs of a wide range of clinical liver disease patients, promote recovery of the regenerative function of liver cells of the patients themselves, or prolong the life span of the patients.
Disclosure of Invention
One of the purposes of the invention is to provide a quality control method of C3A cells required by biotype artificial liver treatment.
The second purpose of the invention is to provide a cell bank of human C3A cell line, which ensures large-scale production of biological artificial liver.
The invention also aims to provide application of the quality control method.
In order to achieve the purpose, the invention adopts the following technical scheme:
according to one aspect of the invention, the invention provides a quality control method of C3A cells required by biotype artificial liver treatment, which ensures the treatment quality of the biotype artificial liver.
Further, the quality control method comprises detecting cell property stability and cell safety;
in a specific embodiment of the present invention, the quality control method comprises the steps of:
1) establishing a main cell bank, detecting the property stability of the cells and detecting the safety of the cells;
2) establishing a manufacturer working cell bank, detecting the property stability of the cells and the safety of the cells;
3) establishing a working cell bank, detecting the property stability of the cells and detecting the safety of the cells;
4) establishing a cell bank after production is finished, detecting the property stability of the cells and detecting the safety of the cells;
further, detecting the stability of the cell property includes detecting the genotype, phenotype and activity of the cell.
In a specific embodiment of the invention, the detection of cell genotype uses a short tandem repeat test.
Genotypes for short tandem repeat testing of the present invention include AMEL, D3S1358, D1S1656, D6S1043, D13S317, Penta E, D16S539, D18S51, D2S1338, CSF1PO, Penta D, TH01, vWA, D21S11, D7S820, D5S818, TPOX, D8S1179, D12S391, D19S433, FGA.
Further, detecting cell safety includes detecting whether microbial contamination exists in the cells, detecting whether viral contamination exists in the cells, detecting whether cross contamination exists between cells, and detecting whether microbial contamination exists in a device for culturing the cells.
Further, the microorganism includes bacteria, fungi, yeast, mycoplasma.
Further, viruses include endogenous viruses and exogenous viruses.
Still further, the virus includes human virus, non-human virus. Preferably, the non-human virus comprises murine virus, porcine virus, bovine virus.
In a particular embodiment of the invention, the human virus comprises HSV-1/2, B19, EBV, SV40, HHV5/CMV, HHV6, HHV7, HHV8, HIV-1, HIV-2, HBV, HCV, HTLV, HAV, HEV.
In a specific embodiment of the invention, the murine virus includes murine pox virus, rat taylor encephalomyelitis virus, lactate dehydrogenase virus, lymphocytic choriomeningitis virus, hantavirus, mouse parvovirus, mouse adenovirus, mouse hepatitis virus, mouse pneumovirus, polyoma virus, sendai virus, juvenile epidemic diarrhea virus, mouse salivary adenovirus (mouse cytomegalovirus), reovirus type 3, virus K, mouse thymic adenovirus, mouse thermophilic retrovirus, mouse retrovirus.
In a particular embodiment of the invention, the porcine virus comprises porcine parvovirus.
Methods for detecting cells and fungi that can be used in the present invention include direct inoculation, membrane filtration.
Methods for detecting mycoplasma that can be used in the present invention include culture assays, non-culture assays.
Further, non-culture assays include microscopy, nucleic acid assays.
Furthermore, the nucleic acid detection comprises a PCR method, a nested PCR method, a fluorescent quantitative PCR method, reverse dot hybridization, surface plasmon resonance biosensor rapid detection, a fluorescence polarization technology and the like.
Methods for detecting viruses that can be used in the present invention include thin layer electron microscopy, infectivity assays, cell co-culture, PCR, PERT, extended XC plaque, extended mink S + L.
In a specific embodiment of the invention, the method of creating a master cell library comprises the steps of: the C3A cells were sub-cultured and expanded at 3X 10 in a cell culture facility6To 1X 107The cell density of the cells/bottles is frozen in a frozen preservation solution; preferably, the cryopreservation solution comprises 10% DMSO, 20% fetal bovine serum, MM medium (available from Shandong Yi Ruite Biotech Co., Ltd.).
In a specific embodiment of the invention, the method of creating a manufacturer's working cell bank comprises the steps of: recovering, culturing and expanding cells in the main cell bank, passaging the cells for 4 times, and averaging the 5 th generation cells to 1.08 × 107The cell density of each cell/bottle is frozen and stored in a frozen and stored solution; preferably, the cryopreservation solution comprises 10% glycerol, 5% fetal bovine serum and MM culture solution.
In a particular embodiment of the invention, the method of establishing a working cell bank comprises the steps of: cells in the manufacturer's working cell bank were recovered, cultured, and expanded by about 107The cell density of each cell/bottle is frozen and stored in a frozen and stored solution; preferably, the cryopreservation solution comprises 20% fetal bovine serum, 10% DMSO, MM culture solution.
In a specific embodiment of the present invention, the method for establishing the production-terminated cell bank comprises the steps of recovering, culturing and passaging the cells in the working cell bank in a culture flask for 7 times, and simulating the whole process of culturing and growing the cells in a bioreactor.
According to another aspect of the invention, the invention provides the use of the method described above for the construction of a C3A cell bank.
Further, the cell bank comprises a main cell bank, a manufacturer working cell bank, a working cell bank and a production end cell bank.
The definition of the master cell bank, the manufacturer's working cell bank, the working cell bank and the end-of-production cell bank is the same as that described above.
According to another aspect of the invention, there is provided the use of a method as hereinbefore described in the preparation of C3A cells for use in the treatment of an artificial liver assist device.
The main cell bank refers to the original cell seeds which are evenly mixed into a batch after passage proliferation, quantitatively packaged and stored in liquid nitrogen or below 130 ℃. And after the cells are completely qualified, the cells are the main cell bank for establishing a working cell bank.
As used herein, the term "manufacturer's working cell bank" refers to a large number of uniformly composed cells obtained from the seeds of cells in a master cell bank, stored in aliquots at temperatures of-130 ℃ or less, for production. In normal practice, cell seed expansion is selected by the manufacturer when subcultured to a certain passage number. The cells are merged into a pool, and the cells are equally divided into bottles to be frozen and stored to obtain the MWCB.
The working cell bank refers to cells which are subjected to subculture proliferation by a manufacturer to reach a certain generation level, are mixed to prepare a batch of homogeneous cell suspension, are quantitatively packaged in a certain number of cell cryopreservation tubes, and are stored in liquid nitrogen or at the temperature of below 130 ℃ below zero for later use. And the cells are qualified through complete verification, and then the cells are the working cell bank.
As used herein, the term "end-of-production cell bank" refers to a cell bank comprised of cells harvested at or beyond the end of production. The method is used for detecting the characteristics and the existence of changes of molecular structure level after cells are cultured for a long time to become products.
The term "Biological Artificial Liver (BAL)" as used herein refers to an in vitro cell bioreactor device constructed on the basis of artificially cultured hepatocytes.
The cell bioreactor is the core of the entire BAL. The cell bioreactors currently studied and applied are mainly the following:
1) hollow fiber type cell bioreactor
Is the most applied type of reactor at present. The hollow fiber tube is divided into an inner cavity and an outer cavity, the fiber membrane is a layer of barrier, the liver cells are generally cultured and grown in the outer cavity at present, the cells grow in a three-dimensional mode, and the membrane can prevent the cells from entering a human body. The reactor has the greatest advantages of huge surface area to volume ratio, convenience for metabolite transportation and minimal dead space. However, the activity and function of the cells are also easily reduced due to uneven distribution of the hepatocytes in the reactor.
2) Flat plate single layer bioreactor
The reactor is used for directly planting the liver cells on a flat plate, and has the advantages that the cells are uniformly distributed, the microenvironment is consistent, but the ratio of the surface area to the volume is reduced, and Shito et al designs a flat plate monolayer bioreactor with an inner membrane oxygenator.
3) Perfusion bed/stent bioreactor
The bioreactor is used for planting the liver cells on an infusion bed or a bracket, the reactor enables the plasma to be directly contacted with the cells, the transfer of substances is increased, the three-dimensional bracket also promotes the formation of the three-dimensional structure of the liver cells, the cell capacity is easily expanded, and the bioreactor has the defects of nonuniform infusion, easy blockage and easy entry of variant cells into a human body.
4) Coating suspension bioreactor
The bioreactor is prepared by wrapping liver cells with a semipermeable membrane material to prepare porous microcapsules, and then performing perfusion culture. Its advantages are the same microenvironment for all cells, and large cell culture space, resulting in less immunoreaction. The disadvantages are poor cell stability, easy clogging of the micropores, limited material exchange capacity and limited cell quantity obtained.
One type of biotype artificial liver commonly used is the in vitro liver assist device (ELAD) designed by scientists at Baylar medical college, USA, vitamin therapeutics, Inc (San Diego, CA, USA) further developed and developed, conceptually similar to an assisted liver, which uses C3A hepatocytes instead of animal hepatocytes, including four hollow fiber dialysis reactors. Before use, a small number of hepatocytes were seeded into each reactor. After a maturation period of 2-3 wk. The cells are replicated and amplified. Each reactor contained approximately 100-120g of hepatocytes. Ultrafiltration (150-. A significant advantage of this filter design is that it can be operated continuously for 10 days without interruption. The ultrafiltration membrane only allows substances with the diameter of 100-120KD to pass through, also called ultrafiltrate
The invention has the advantages and beneficial effects that:
the invention discloses the quality control that the C3A cell needed by the preparation of the biotype artificial liver therapy must carry out for the first time. Only through the quality control, the C3A cell with stable cell property and strong safety can be obtained.
The invention firstly constructs a C3A cell bank which is divided into a main cell bank, a manufacturer working cell bank, a working cell bank and a production end cell bank according to different purposes. Enough cell freezing bottles are stored in the cell bank, high-quality fresh cultured cells can be continuously provided according to the requirement, and the large-scale mass production of the high-quality biological cell reactor can be ensured.
Drawings
FIG. 1 shows a flow chart for the construction of a final cell bank.
Detailed Description
The present invention is described in detail below by way of examples, it should be noted that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention, and those skilled in the art can make some insubstantial modifications and adaptations of the present invention based on the above-described disclosure. In the following examples, the reagents used were all analytical grade and were commercially available unless otherwise indicated. Experimental procedures not specifically identified herein are generally carried out under conventional conditions such as those described in the molecular cloning guidelines, published by scientific Press 2002, edited by J. SammBruk et al, or under conditions recommended by the manufacturer. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention.
Examples preparation, production, characterization of cell banks and safety testing of adventitious agents
1. Master cell library construction
C3A cells were cultured and maintained in a cell culture facility. C3A cells were sub-cultured and expanded until there were enough cells to grow at 3X 106To 1X 107Cells/flasks were cryopreserved. Collecting cells at logarithmic growth phase, using
NC-3000TMAn advanced image cytometer uses fluorescence imaging to characterize cell characteristics and viable cell viability indexes for cell counting. After centrifugation to remove the culture supernatant, the cells were resuspended at the desired concentration in a cryopreservative containing 10% dimethylsulfoxide and 20% fetal bovine serum. The resuspended cells were dispersed in a cryovial. 140 vials containing cells of the Master Cell Bank (MCB, Master Cell Bank) were prepared, each vial containing 3X 10 cells6To 1X 107(average 5.07X 10)6) And (4) living cells. The cryopreservation solution containing 10% dimethyl sulfoxide and 20% fetal bovine serum refers to MM culture solution containing 10% DMSO and 20% fetal bovine serum (available from Shandong Yi Rui Tech Biotech Co., Ltd.).
Isoenzyme analysis was also performed to confirm that these cells were of human origin. Table 1 lists the results of testing MCB under GLP conditions. These results demonstrate the identity and genetic stability of C3A cells in MCB. It was also confirmed that MCB tested did not contain endogenous or exogenous viruses, retroviruses and other endogenous viruses. Note: in table 1 "unobvious virus" is recessive infection, subclinical infection; infection without clinical symptoms. Lymphocytic choriomeningitis virus (LCMV) is a rodent transmitted sandtype virus that causes insignificant infection).
TABLE 1 detection results of MCB cell characteristics
2. Production Manufacturer's Working Cell Bank (MWCB) construction
Cell expansion was started from C3A in a vial of MCB. Cells were passaged four times and stored frozen at passage 5 in MM medium containing 10% glycerol and 5% fetal bovine serum owned by Shandong Yiruite Biotech, Inc. In total 107 vials were produced, each vial containing on average 1.08X 107The average survival rate of each cell reaches 78 percent.
Table 2 lists the extrinsic factor (e.g., virus and mycoplasma) tests performed on C3A MWCB. The test results confirm that the identity of the MWCB is preserved and maintained.
TABLE 2 detection results of MWCB cell characteristics
| Description of the detection | Results | |
| 1 | Sterility testing by direct inoculation (bacteria and fungi) | No growth |
| 2 | Mycoplasma (PTC) | Negative of |
| 3 | In vitro determination of foreign viral contaminants (protocol #003031) | No detection out |
| 4 | In vitro assay for foreign viral contaminants (protocol #005002) | No detection out |
| 5 | Analytical identification and characterization of cell cultures using the isozyme method | Human origin |
| 6 | Identity recognition by short tandem repeat analysis | 100% identity |
3. Construction of Working Cell Bank (Working Cell Bank, WCB)
Two MWCB vials were used to produce the C3A Working Cell Bank (WCB). Using a protocol and procedure similar to MWCB production to produce 200 WCB vials, cells were suspended in 20% fetal bovine serum (BCS), 10% DMSO, and cryo-fluid equilibrated with MM medium, averaging about 107 cells per vial. The tests performed on the final WCB vials are shown in table 3. The four media in table 3 refer to: 1) soy casein digestion broth (TSB); 2) thioglycolic acid liquid broth (THIO); 3) saxifrage glucose agar; 4) sterile Phosphate Buffered Saline (PBS) was used as a negative control for inoculation.
TABLE 3 WCB cell characterization assay
4. Production of End cell Bank (End of Production Cells Bank, EOPCB)
A study at the end of production was initiated using a standard C3A cell culture expansion procedure. Cells were passaged 8 times within 8 weeks, estimated to correspond to about 16-24 cell doublings. Once C3A cells were seeded into the ELAD C3A cell reactor, it was estimated that the reactor would produce an effect equivalent to 7 additional passages. However, since cells were not restored after introduction into the cell reactor, the study in this section simulated cell growth/production in the ELAD C3A cell reactor using T225 culture flasks. These cells were subjected to an additional 7 passages over a period of 7 weeks in T225 flasks, estimated to correspond to 14-21 additional doublings. Based on this design, the cells tested at the end of the production study were 15 weeks old, undergoing a total of about 15 passages, corresponding to approximately 30-45 doublings. During the course of this study, cells were exposed to fresh medium (containing bovine serum) approximately 45 times. A flow chart for the preparation of the final cell bank is shown in FIG. 1.
Viral safety and characterization tests were performed at the end of the in vitro cell age limit and showed that the cells retained their identity as C3A cells at the end of production and were free of viral contaminants. The test results are provided in table 4.
The 14 viruses (Human specific Type I) in Table 4 refer to HSV-1/2 (Human Simplex Virus Types 1 and 2, Herpes Simplex viruses 1 and 2), B19 (parvovirus B19), EBV (Epstein-Barr Virus ), SV40(Simian Virus 40, Type Simian Virus 40), HHV5/CMV (Human Herpesvirus Type 5/Human Cytomalogovirus, Human Herpesvirus Type 5/Human Cytomegalovirus), HHV6(Human Herpesvirus Type 6, Type 6 Human Herpesvirus), HHV7(Human Herpesvirus Type 7, Type 7 Human Herpesvirus), HHV8(Human Herpesvirus Type 8, Type 8 Human Herpesvirus), HIV-1(Human Immunodeficiency Virus Type 1, Type 2), HIV-Immunodeficiency Virus (Human Immunodeficiency Virus Type 2, HIV-Type 2), hepatitis b Virus), HCV (Hepatitis C Virus), HTLV (Human T cell Leukemia Virus), HAV (Hepatitis a Virus).
The 17 murine viruses in Table 4 are Mouse pox Virus (Ectromlia Virus), rat taylor encephalomyelitis Virus (GDVII), Lactate Dehydrogenase Virus (LDV)), Lymphocytic Choriomeningitis Virus (Lymphatic Choriomeningitis Virus), Hantaan Virus (Hantaan Virus), Mouse Parvovirus (MMV), Mouse Parvovirus (MPV), Mouse Adenovirus (Mouse Adenovirus), Mouse Hepatitis Virus (Mouse Hepatitis Virus (MHV)), Mouse Pneumonia Virus (Pneumonia Virus of Mice (PVM)), Polyoma Virus (Polyvirus), Sendai Virus (Sendai Virus), Mouse epidemic Diarrhea Virus (III Virus of Mouse), Mouse Adenovirus (III Virus of Mouse saliva Virus (MCIV) and Mouse Adenovirus (III), Mouse Adenovirus (III Virus of Mouse saliva Virus (III)), and Mouse Adenovirus (III Virus of Mouse saliva Virus (III) (GDVII), Mouse Adenovirus (III), Mouse Adenovirus of Mouse saliva Virus (III) and Mouse Adenovirus (III) 3) (Mouse Adenovirus of Mouse Adenovirus (III) and Mouse Adenovirus (III, Mouse Adenovirus of Mouse Adenovirus (III) and Mouse Adenovirus (III) are provided with the same Virus strain of Mouse Adenovirus (III, Mouse Adenovirus (III) and Mouse Adenovirus of Mouse Adenovirus (III) and Mouse Adenovirus (III, K Virus, Mouse Thymic Virus (MTV)).
TABLE 4 EPCB (end of Production Cells Bank) Production end cell characterization
As part of the cell characterization test, a Short Tandem Repeat (STR) test was used to confirm the genotype of the C3A cell bank. The results are shown in table 5, which shows that all cell banks retain their identity and characteristics as C3A cells without any variation or change.
TABLE 5C 3A cell bank STR detection
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Claims (10)
1. A quality control method of C3A cells required by biotype artificial liver treatment is characterized in that the quality control method comprises the steps of detecting the stability of cell properties and detecting the safety of cells;
preferably, the quality control method comprises the steps of:
1) establishing a main cell bank, detecting the property stability of the cells and detecting the safety of the cells;
2) establishing a manufacturer working cell bank, detecting the property stability of the cells and the safety of the cells;
3) establishing a working cell bank, detecting the property stability of the cells and detecting the safety of the cells;
4) establishing a production terminal cell bank, detecting the property stability of the cells and detecting the safety of the cells;
preferably, measuring the stability of a cell property comprises measuring the genotype, phenotype, activity of the cell.
2. The method of claim 1, wherein detecting the genotype of the cell is performed using a short tandem repeat test;
preferably, the genotypes used for the short tandem repeat test include AMEL, D3S1358, D1S1656, D6S1043, D13S317, Penta E, D16S539, D18S51, D2S1338, CSF1PO, Penta D, TH01, vWA, D21S11, D7S820, D5S818, TPOX, D8S1179, D12S391, D19S433, FGA.
3. The method of claim 1, wherein detecting cell safety comprises detecting the presence of microbial contamination of cells, detecting the presence of viral contamination of cells, detecting the presence of cell cross-contamination of cells, detecting the presence of microbial contamination of a device in which cells are cultured;
preferably, the microorganism includes bacteria, fungi, yeasts, mycoplasma;
preferably, the virus includes endogenous and exogenous viruses;
preferably, the virus comprises a human virus, a non-human virus; more preferably, the non-human viruses include murine viruses, porcine viruses, bovine viruses;
preferably, the human viruses include HSV-1/2, B19, EBV, SV40, HHV5/CMV, HHV6, HHV7, HHV8, HIV-1, HIV-2, HBV, HCV, HTLV, HAV, HEV;
preferably, the murine virus includes murine pox virus, rat taylor encephalomyelitis virus, lactate dehydrogenase virus, lymphocytic choriomeningitis virus, hantavirus, mouse parvovirus, mouse adenovirus, mouse hepatitis virus, mouse pneumovirus, polyoma virus, sendai virus, juvenile epidemic diarrhea virus, mouse salivary adenovirus, reovirus type 3, virus K, mouse thymic adenovirus, mouse thermophilic retrovirus, mouse retrovirus;
preferably, the porcine virus comprises porcine parvovirus.
4. The method of claim 3, wherein the method for detecting cells and fungi comprises direct seeding, membrane filtration.
5. The method of claim 3, wherein the method for detecting the virus comprises thin layer electron microscopy, infectivity assay, cell co-culture, PCR, PERT, extended XC plaque, extended mink S + L.
6. The method of claim 1, wherein the method of creating a master cell library comprises the steps of: the C3A cells were sub-cultured and expanded at 3X 10 in a cell culture facility6To 1X 107The cell density of the cells/bottles is frozen in a frozen preservation solution; preferably, the cryopreservation solution comprises 10% DMSO, 20% fetal bovine serum, MM culture solution.
7. The method of claim 1, wherein the method of creating a manufacturer's working cell bank comprises the steps of: recovering, culturing and amplifying cells in the main cell bank, passaging the cells for 4 times, and averaging the 5 th generation cells to 1.08 × 107The cell density of each cell/bottle is frozen and stored in a frozen and stored solution; preferably, the cryopreservation solution comprises 10% glycerol, 5% fetal bovine serum and MM culture solution.
8. The method of claim 1, wherein the method of creating a working cell bank comprises the steps of: cells in the manufacturer's working cell bank were recovered, cultured, and expanded by about 107The cell density of each cell/bottle is frozen and stored in a frozen and stored solution; preferably, the cryopreservation solution comprises 20% fetal bovine serum, 10% DMSO, MM culture solution.
9. The method of claim 1, wherein the method of establishing a final cell bank comprises resuscitating, culturing, and passaging 7 times the cells in the working cell bank in a culture flask.
10. An application, characterized in that the application is as described in any of the following:
1) use of the method of any one of claims 1-9 to construct a bank of C3A cells; preferably, the cell bank comprises a cell bank, a manufacturer's working cell bank, a production end cell bank;
2) use of the method of any one of claims 1-9 for the preparation of C3A cells for biotype artificial liver therapy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020115266249 | 2020-12-22 | ||
| CN202011526624 | 2020-12-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112680529A true CN112680529A (en) | 2021-04-20 |
| CN112680529B CN112680529B (en) | 2023-03-17 |
Family
ID=75453731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011619362.0A Active CN112680529B (en) | 2020-12-22 | 2020-12-31 | Quality control method of C3A cells required by biotype artificial liver treatment and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112680529B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373267A (en) * | 2021-07-16 | 2021-09-10 | 浙江大学 | Multiplex fluorescence quantitative RT-PCR kit for detecting blood-borne infectious viruses |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107557475A (en) * | 2017-07-03 | 2018-01-09 | 深圳华大法医科技有限公司 | Composite amplification system, kit for 23 STR bit points of people and application thereof |
| CN107841567A (en) * | 2017-12-13 | 2018-03-27 | 苏州阅微基因技术有限公司 | Composite amplification system, kit and the application of 28 STRs |
| CN112342191A (en) * | 2019-08-07 | 2021-02-09 | 路春光 | hMSC production kit development and quality management standard optimization and system establishment |
-
2020
- 2020-12-31 CN CN202011619362.0A patent/CN112680529B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107557475A (en) * | 2017-07-03 | 2018-01-09 | 深圳华大法医科技有限公司 | Composite amplification system, kit for 23 STR bit points of people and application thereof |
| CN107841567A (en) * | 2017-12-13 | 2018-03-27 | 苏州阅微基因技术有限公司 | Composite amplification system, kit and the application of 28 STRs |
| CN112342191A (en) * | 2019-08-07 | 2021-02-09 | 路春光 | hMSC production kit development and quality management standard optimization and system establishment |
Non-Patent Citations (1)
| Title |
|---|
| 国家食品药品监督管理局药品认证管理中心: "《ICH质量管理文件汇编》", 31 January 2010 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373267A (en) * | 2021-07-16 | 2021-09-10 | 浙江大学 | Multiplex fluorescence quantitative RT-PCR kit for detecting blood-borne infectious viruses |
| CN113373267B (en) * | 2021-07-16 | 2022-04-29 | 浙江大学 | Multiplex fluorescence quantitative RT-PCR kit for detecting blood-borne infectious viruses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112680529B (en) | 2023-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Masters | Animal cell culture: a practical approach | |
| US11629338B2 (en) | Method for acclimating and suspending Vero and second order production process for virus | |
| CN112680529B (en) | Quality control method of C3A cells required by biotype artificial liver treatment and application thereof | |
| Carmelo et al. | Scalable ex vivo expansion of human mesenchymal stem/stromal cells in microcarrier-based stirred culture systems | |
| Fernandes-Platzgummer et al. | Clinical-grade manufacturing of therapeutic human mesenchymal stem/stromal cells in microcarrier-based culture systems | |
| CN115505559A (en) | Development method of HEK293 suspension cell line for virus vector production | |
| CN112126618B (en) | Method for obtaining human gallbladder stem cells and long-term in vitro culture | |
| Schoofs et al. | A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy | |
| CN111411073A (en) | Construction method of sea bass fry cell line | |
| CN111424011A (en) | Three-dimensional culture method capable of maintaining cell morphology of umbilical cord mesenchymal stem cells | |
| CN116355857B (en) | Suspension-cultured bovine kidney cells, and preparation method and application thereof | |
| CN106591216B (en) | Human normal corneal epithelial cell and application thereof | |
| CN110592001B (en) | Purification culture system for oviduct epithelial cells | |
| Gürdal et al. | Comparison of culture media indicates a role for autologous serum in enhancing phenotypic preservation of rabbit limbal stem cells in explant culture | |
| CN110499279A (en) | A method of induce human urine derived stem cells to hepatocyte differentiation | |
| CN109666643A (en) | One plant of cervical intraepithelial neoplasia (CIN) cell line and application thereof containing sequestered HPV18 | |
| CN115651887A (en) | Application of human normal corneal epithelial cells | |
| Ikonomou et al. | Microcarrier culture of lepidopteran cell lines: implications for growth and recombinant protein production | |
| CN110872572B (en) | Method for improving in-vitro suspension culture efficiency of human multifunctional stem cells | |
| Andreeva et al. | Isolation and expansion of mesenchymal stem cells from murine adipose tissue | |
| Chen et al. | Facile suspension culture protocol of the liver biliary organoids | |
| Tasto et al. | Towards a Continuous Production of Human Mesenchymal Stromal Cells in a Chemically Defined Medium: Opportunities and Challenges for a Robust and Scalable Expansion Process | |
| Wu et al. | Comparisons of microcarrier cell culture processes in one hundred mini-liter spinner flask and fifteen-liter bioreactor cultures | |
| CN117402813B (en) | Establishment, suspension domestication and application of cat kidney CRFK adherent cell line | |
| CN110804584B (en) | Optimized umbilical cord mesenchymal stem cell culture solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |